LINC01138 and hepatocellular carcinoma: To further determine the oncogenic properties of LINC01138 in HCC, we used the CRISPR/dead-Cas9 system to activate the endogenous RNA level of LINC0113820 and the CRISPR/Cas9 system to knockout the endogenous RNA level of LINC01138 (Supplementary Fig. 4a)21.